Popular weight loss drugs such as Wegovy and Zepbound have shown incredible success in clinical trials. But in the real world ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.